Sleep Apnea Treatment With Expiratory Resistance(Provent™)

Johns Hopkins University12 enrolled

Overview

Continuous positive airway pressure (CPAP) continues to be the primary therapy prescribed for the treatment of obstructive sleep apnea (OSA). Although effective, adherence to CPAP is suboptimal in many patients, making alternative therapies desirable. Recently, a novel device (Provent™) has been developed for the treatment of snoring and OSA. The purpose of the current study is to examine how well the Provent™ device treats OSA with particular attention to the how the it may treat sleep apnea and who may most likely benefit from the use of this treatment.

Study Type

INTERVENTIONAL

Allocation

Masking

NONE

Enrollment

Conditions

Sleep Apnea, Obstructive

Interventions

Treatment sleep study (Provent™ device used)DEVICE

The patient's sleep apnea severity is determined on this night while using the Provent™ device. The patient only uses the Provent™ device on this night (single night use only).

Baseline sleep study (No device)OTHER

The patient sleeps for 1 night in the sleep lab to determine their baseline sleep apnea severity without sleeping with the Provent device.

Physiology sleep study (Provent™ on/off)OTHER

During this sleep study night, the patient is sleeping with a modified Provent™ device that can be turned on and off to assess changes in airflow during the night (single night use only).Provent™ on/off is bracketed in 10 minute intervals during stable stage 2 sleep.

Eligibility

Sex: ALLMin age: 21 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Consenting adults over the age of 18 * Diagnosed obstructive sleep apnea (defined as an RDI \> 5 events per hour \& ≥ 90% of disordered breathing events classified as obstructive) Exclusion Criteria: * Total sleep time from previous sleep study \< 4 hours (240 minutes) * Severe bilateral nasal obstruction (apparent mouth breathing at rest) * Documented history of lung diseases, as defined below: * Daytime hypercapnia (PaCO2 \> 45 mmHg) * Baseline SaO2 ≤ 92% * Chronic lung disease except mild intermittent or mild persistent asthma * Cor pulmonale * Documented clinical cardiovascular disease, as defined below: * Myocardial infarction in past 3 months * Revascularization procedure in past 3 months * Implanted cardiac pacemaker or ICD * Unstable arrhythmias * Congestive heart failure with ejection fraction \< 40% * Uncontrolled hypertension (BP \> 190/110) * History of end stage renal disease (on dialysis) * History of end stage liver disease, such as: * Jaundice * Ascites * History of recurrent gastrointestinal bleeding * Transjugular intrahepatic portosystemic shunt (TIPS) ; * Sleep disorders other than obstructive sleep apnea, such as: * Narcolepsy * Restless leg syndrome * Periodic limb movements causing an arousal index of \> 5 per hour * Transportation industry worker (commercial truck or bus drivers, airline pilots) * Known pregnancy (by self report) * Known coagulopathy or anticoagulant use (e.g. coumadin) other than aspirin. * Allergy to lidocaine

Locations (1)

Johns Hopkins Asthma and Allergy Center

Baltimore, Maryland, United States

Outcomes

Primary Outcomes

Change in AHI

The primary outcome was the change in the apnea hypopnea index (AHI). Sleep apnea events are defined as apneas and hypopneas.The AHI is a measure of sleep apnea severity. An AHI \> 5 event/h is considered abnormal. AHI values are typically categorized as 5-15 events/hr = mild; 15-30 events/hr = moderate; and \> 30 events/hr = severe. For this study we compared the change in AHI from the baseline sleep study (No Provent) compared to the treatment night sleep study (on Provent).

Time frame: Comparisons were made between the 2 nights

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.